SG11201607106YA - Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder - Google Patents

Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Info

Publication number
SG11201607106YA
SG11201607106YA SG11201607106YA SG11201607106YA SG11201607106YA SG 11201607106Y A SG11201607106Y A SG 11201607106YA SG 11201607106Y A SG11201607106Y A SG 11201607106YA SG 11201607106Y A SG11201607106Y A SG 11201607106YA SG 11201607106Y A SG11201607106Y A SG 11201607106YA
Authority
SG
Singapore
Prior art keywords
prevention
treatment
pyridazine derivatives
ataxic disorder
ataxic
Prior art date
Application number
SG11201607106YA
Inventor
Sarah Almond
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201607106Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of SG11201607106YA publication Critical patent/SG11201607106YA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201607106YA 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder SG11201607106YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use
PCT/GB2015/050654 WO2015132608A1 (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Publications (1)

Publication Number Publication Date
SG11201607106YA true SG11201607106YA (en) 2016-09-29

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201607106YA SG11201607106YA (en) 2014-03-06 2015-03-06 Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder

Country Status (31)

Country Link
US (1) US20170014407A1 (en)
EP (1) EP3113778B1 (en)
JP (1) JP6510549B2 (en)
KR (1) KR20160126081A (en)
CN (1) CN106102743A (en)
AU (1) AU2015225954B2 (en)
CA (1) CA2940342A1 (en)
CL (1) CL2016002151A1 (en)
CY (1) CY1120573T1 (en)
DK (1) DK3113778T3 (en)
EA (1) EA036438B1 (en)
ES (1) ES2676905T3 (en)
GB (1) GB201403944D0 (en)
GE (1) GEP20196984B (en)
HR (1) HRP20181082T1 (en)
IL (1) IL247435A0 (en)
LT (1) LT3113778T (en)
MA (1) MA39315A1 (en)
MX (1) MX2016010524A (en)
MY (1) MY186475A (en)
PH (1) PH12016501751A1 (en)
PL (1) PL3113778T3 (en)
PT (1) PT3113778T (en)
RS (1) RS57594B1 (en)
SG (1) SG11201607106YA (en)
SI (1) SI3113778T1 (en)
TR (1) TR201809537T4 (en)
TW (1) TW201534591A (en)
UA (1) UA123352C2 (en)
WO (1) WO2015132608A1 (en)
ZA (1) ZA201604611B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
WO2015168010A1 (en) 2014-04-29 2015-11-05 E. I. Du Pont De Nemours And Company Pyridazinone herbicides
TWI785022B (en) 2017-03-28 2022-12-01 美商富曼西公司 Novel pyridazinone herbicides
EP3645515B1 (en) 2017-06-30 2021-11-03 FMC Corporation 4-(3,4-dihydronaphth-1-yl or 2h-chromen-4-yl)-5-hydroxy-2h-pyradizin-3-ones as herbicides
CN112569217B (en) * 2019-09-30 2022-04-22 厦门大学 Application of valeric acid derivatives in treating hereditary cerebellar ataxia
JP2021138648A (en) 2020-03-04 2021-09-16 武田薬品工業株式会社 Oral solid preparation
AU2022228417A1 (en) 2021-03-01 2023-10-26 Neurocrine Biosciences, Inc. Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2262322T3 (en) * 1998-06-10 2006-11-16 Meiji Seika Kaisha, Ltd. TREATMENT OF SPINOCEREBERAL DEGENARATION AND USEFUL COMOPOSITIONS FOR THE TREATMENT OF SPINOCEREBELAR DEGENERATION.
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (en) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co Pyridazinone Compounds and Their Use as DAAO Inhibitors

Also Published As

Publication number Publication date
ZA201604611B (en) 2017-09-27
PL3113778T3 (en) 2018-11-30
WO2015132608A1 (en) 2015-09-11
KR20160126081A (en) 2016-11-01
PH12016501751A1 (en) 2017-02-06
GB201403944D0 (en) 2014-04-23
CL2016002151A1 (en) 2016-12-30
HRP20181082T1 (en) 2018-09-07
EA201691566A1 (en) 2016-12-30
CY1120573T1 (en) 2019-07-10
UA123352C2 (en) 2021-03-24
JP6510549B2 (en) 2019-05-08
PT3113778T (en) 2018-07-11
TW201534591A (en) 2015-09-16
MX2016010524A (en) 2016-10-31
JP2017507156A (en) 2017-03-16
DK3113778T3 (en) 2018-07-30
MY186475A (en) 2021-07-22
RS57594B1 (en) 2018-11-30
SI3113778T1 (en) 2018-08-31
EP3113778A1 (en) 2017-01-11
GEP20196984B (en) 2019-06-25
IL247435A0 (en) 2016-11-30
US20170014407A1 (en) 2017-01-19
LT3113778T (en) 2018-08-27
EP3113778B1 (en) 2018-06-06
ES2676905T3 (en) 2018-07-26
EA036438B1 (en) 2020-11-11
CN106102743A (en) 2016-11-09
AU2015225954A1 (en) 2016-07-07
TR201809537T4 (en) 2018-07-23
MA39315A1 (en) 2017-09-29
AU2015225954B2 (en) 2020-06-18
CA2940342A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
PL3157512T3 (en) Use of cannabidiol in the treatment of epilepsy
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
HRP20190194T1 (en) 17a,21-diesters of cortexolone for use in the treatment of tumors
IL247435A0 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
IL251905B (en) Apilimod for use in the treatment of renal cancer
IL251903B (en) Apilimod for use in the treatment of colorectal cancer
IL252493B (en) Compounds for use in the prevention or treatment of cancer
GB201511772D0 (en) Improvements in the treatment of ash
GB201415876D0 (en) Methods for the treatment and prevention of Ebola